Hikma Pharmaceuticals PLC

1,650pAs of Sun 8 Nov 2026, 12:00 UTC
LSE:HIKHealthcare
Ctry United Kingdom
PE (Fwd) •••
TSR 10Y CAGR 1.88%
Div yield 3.76%
ROE 15.41%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.62
PE TTM 12.46
TSR TTM (6.09%)
Mkt cap £3.419B
ROIC 12.40%
SE Grade™
Value
Quality
Moat
Consensus
Reference
1,925p
16.68%
23.28%
Hold 12|6|1|9|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
26.13
27.92
30.44
33.23
9.62%
7.55%
10.29%
22.11%
Revenue$M
333.2
328.2
324.8
324.1
15.69%
9.41%
5.17%
2.63%
Peers (US$4.601B)
Cap (US$)
PE
40.09B
18.72x
2.573B
144.6x
4.680B
9.051x
Capital
TTM
5Y
10Y
Leveragex
0.392
1.753
1.266
EBIT/Intx
1.216
0.065
0.073
Own earn%
(19.90)
(39.44)
(31.65)
Sh yield%
32.39
30.44
26.22
Owners
Insiders/Inst%
14.62
76.44
Short interest%
3.00
SBC / revenue%
4.31
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
11–14
$1 testx
0.1
Incr. ROIC%
2